NDA 050710 · Pfizer
Zithromax
Azithromycin · Oral
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Oct 19, 1995
Approved uses
4
Original approval plus efficacy supplements
Registered trials
627
181 Phase 3, 43 recruiting
FAERS reports
19,146
13,050 serious, 1,467 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 24, 2026.
ZITHROMAX is a macrolide antibacterial drug indicated for treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: • Acute bacterial exacerbations of chronic bronchitis in adults ( 1.1 ) • Acute bacterial sinusitis in adults ( 1.1 ) • Uncomplicated skin and skin structure infections in adults ( 1.1 ) • Urethritis and cervicitis in adults ( 1.1 ) • Genital ulcer disease in men ( 1.1 ) • Acute otitis media in pediatric patients (6 months of age and older) ( 1.2 ) • Community-acquired pneumonia in adults and pediatric patients (6 months of age and older) ( 1.1 , 1.2 ) • Pharyngitis/tonsillitis in adults and pediatric patients (2 years of age and older) ( 1.1 , 1.2 ) Limitation of Use: ZITHROMAX is not recommended in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX and other antibacterial drugs, ZITHROMAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) 1.1 Indications in Adult Patients ZITHROMAX is indicated in adult patients for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: • Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae . • Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis . or Streptococcus pneumoniae . • Community‑acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus...
Mechanism: Azithromycin is a macrolide antibacterial drug. [see Microbiology (12.4) ] Mechanism of Action Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit. Resistance Azithromycin demonstrates cross resistance with erythromycin. The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often by methylation. Ribosomal modifications can determine cross resistance to other macrolides, lincosamides, and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 14, 2001 Supplement 9 · Efficacy LabelLetter
- Dec 14, 2001 Supplement 8 · Efficacy LabelLetter
- Dec 20, 1996 Supplement 1 · Efficacy
- Oct 19, 1995 Original approval · Type 3 - New Dosage Form Other Important Information from FDA
2 products under this application
- ZITHROMAX · AZITHROMYCIN EQ 100MG BASE/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
- ZITHROMAX · AZITHROMYCIN EQ 200MG BASE/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Azithromycin" as an intervention, any sponsor and status, largest first.
- Azithromycin for Child Survival in Niger IIPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06358872 · 3,300,000 participants (planned) · Start Apr 29, 2024 · Primary completion Apr 29, 2028
Drug: Azithromycin for Oral Suspension · For: Mortality; Antimicrobial Resistance
Sites: Niamey, Niger
- Azithromycin for Child Survival in Niger: Mortality and Resistance TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04224987 · 864,493 participants · Start Nov 24, 2020 · Primary completion Jul 31, 2024
Drug: Azithromycin · For: Mortality; Resistance Bacterial; Child, Only
Sites: Niamey, Niger
FHI 360Academic, hospital or other
NCT05016895 · 767,535 participants · Start Aug 27, 2021 · Primary completion Jun 30, 2024
Drug: Single-dose azithromycin · For: Child Mortality
Sites: Abidjan, Côte d’Ivoire
- Infant Mortality Reduction by the Mass Administration of AzithromycinPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT04716712 · 694,400 participants (planned) · Start Oct 4, 2021 · Primary completion Jan 30, 2025
Drug: Azithromycin; Placebo · For: Child Mortality
Sites: San Francisco, California; Nouna, Burkina Faso; Ouagadougou, Burkina Faso
- Kebele Elimination of Trachoma for Ocular HealthPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT03335072 · 320,000 participants (planned) · Start Feb 7, 2022 · Primary completion Mar 1, 2027
Drug: Azithromycin · For: Trachoma
Sites: San Francisco, California; Bahir Dar, Ethiopia
- Mortality Reduction After Oral Azithromycin: Mortality StudyPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT02047981 · 190,238 participants · Start Dec 2014 · Primary completion Sep 2018
Drug: Azithromycin; Placebo · For: Childhood Mortality
Sites: San Francisco, California; Baltimore, Maryland; Blantyre, Malawi · 6 sites in all
- Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)Pivotal-lookingTerminated
University of California, San FranciscoAcademic, hospital or other
NCT05288023 · 169,707 participants · Start Dec 1, 2022 · Primary completion Jan 15, 2024
Drug: Azithromycin for Oral Suspension · For: Resistance Bacterial; Morality; Child Health and 1 more
Sites: San Francisco, California
- Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in MaliPivotal-lookingCompleted
Tampere UniversityAcademic, hospital or other
NCT04424511 · 149,201 participants · Start Oct 15, 2020 · Primary completion Dec 31, 2024
Drug: Placebo; Azithromycin · For: Mortality
Sites: Bamako, Mali
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity1,997
- dyspnoea1,466
- drug ineffective1,199
- nausea1,133
- pain1,088
- diarrhoea1,040
- off label use1,014
- fatigue1,013
- pneumonia990
- headache951
- cough917
- anxiety883
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 585 |
| 2005 | 655 |
| 2006 | 627 |
| 2007 | 381 |
| 2008 | 456 |
| 2009 | 562 |
| 2010 | 951 |
| 2011 | 927 |
| 2012 | 1,059 |
| 2013 | 740 |
| 2014 | 905 |
| 2015 | 1,130 |
| 2016 | 1,333 |
| 2017 | 1,066 |
| 2018 | 1,335 |
| 2019 | 1,273 |
| 2020 | 1,191 |
| 2021 | 904 |
| 2022 | 774 |
| 2023 | 716 |
| 2024 | 639 |
| 2025 | 545 |
| 2026 | 392 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zithromax* (Azithromycin)
2024 spending
$20K
Beneficiaries
708
1,040 claims
Per beneficiary
$29
$2.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $50,470 |
| 2021 | $33,893 |
| 2022 | $26,479 |
| 2023 | $25,423 |
| 2024 | $20,386 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Azithromycin for prevention of exacerbations of COPD.
Albert RK, Connett J, Bailey WC, et al. · N Engl J Med 2011 · Multicenter Study, Randomized Controlled Trial
- Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial.
Ghimire JJ, Jat KR, Sankar J, et al. · Chest 2022 · Randomized Controlled Trial
- Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin.
Tao T, Tao L · Eye (Lond) 2020 · Meta-Analysis, Systematic Review
- Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial.
O'Brien KS, Arzika AM, Amza A, et al. · N Engl J Med 2024 · Adaptive Clinical Trial, Randomized Controlled Trial
- Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
Kobbernagel HE, Buchvald FF, Haarman EG, et al. · Lancet Respir Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.
Gibson PG, Yang IA, Upham JW, et al. · Lancet 2017 · Multicenter Study, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.